Ketamine does appear to reduce certain markers of brain inflammation, particularly at low, subanesthetic doses. A single infusion at 0.5 mg/kg has been shown to lower levels of TNF-α, a key inflammatory signaling molecule, within 40 minutes of administration. But the relationship between ketamine and neuroinflammation is more complex than a simple yes or no. The drug’s effects depend heavily on the dose, the duration of treatment, and which inflammatory markers you measure.
How Ketamine Calms Inflammatory Signaling
The brain’s immune cells, called microglia, are central to neuroinflammation. When activated by injury or chronic stress, they shift into an inflammatory state and release signaling molecules that can damage surrounding neurons. Ketamine appears to reverse this process by nudging microglia back toward a less inflammatory profile and restoring normal cellular cleanup processes (autophagy) that get disrupted during inflammation.
At the molecular level, ketamine targets one of the body’s master inflammatory switches: the NF-κB pathway. This pathway controls the expression of genes responsible for producing inflammatory molecules like TNF-α and IL-1β. Research published in Advanced Science found that S-ketamine (the form used in the nasal spray esketamine) strengthens the activity of a protein called SIRT2, which essentially dials down NF-κB signaling. The result is reduced production of inflammatory molecules in the brain’s prefrontal cortex, the region most closely linked to mood regulation. Notably, R-ketamine, the other mirror-image form of the molecule, did not produce the same anti-inflammatory effect through this pathway.
Which Inflammatory Markers Change, and When
Not all inflammatory markers respond to ketamine the same way, and timing matters considerably. In a randomized, double-blind study of patients with treatment-resistant depression, a single low-dose ketamine infusion reduced TNF-α levels at both 40 minutes and 240 minutes after treatment. A separate study found modest but statistically significant decreases in IL-6 and IL-1α at the 240-minute mark. However, CRP, another common inflammation marker, did not change significantly after a single infusion.
The picture gets more complicated with repeated dosing. Animal studies show that multiple consecutive doses of ketamine consistently decrease TNF-α across a range of doses, but they simultaneously increase IL-6 and IL-1β in the hippocampus. Chronic administration over six months produced the same split pattern: TNF-α went down while other inflammatory markers went up. This suggests ketamine doesn’t simply suppress all inflammation. It reshapes the inflammatory landscape in ways researchers are still working to fully understand.
Dose Determines Protection or Harm
One of the clearest findings in ketamine research is that the dose makes the difference between neuroprotection and neurotoxicity. At subanesthetic doses (below 0.5 mg/kg intravenously in humans), ketamine activates neurotrophic signaling cascades that promote cell survival and the production of brain-derived growth factors. For context, the standard dose used in depression treatment is 0.5 mg/kg infused over 40 minutes, well below the 1 to 4.5 mg/kg range used for surgical anesthesia.
Animal research illustrates the threshold vividly. A dose of 5 mg/kg was found to prevent the widespread brain cell death caused by higher anesthetic doses of 20 mg/kg. Meanwhile, doses of 40 mg/kg and above caused visible damage to neurons in specific brain regions. At 80 mg/kg, inflammatory cytokine production in the hippocampus increased regardless of how the drug was administered. At anesthetic doses given during critical developmental windows, ketamine actually contributes to inflammation, uncontrolled cell death, and oxidative stress, the opposite of its effects at lower doses.
The Depression Connection
The link between ketamine’s anti-inflammatory properties and its rapid antidepressant effects is one of the more compelling threads in this research. Depression is increasingly understood as having an inflammatory component. Many patients with treatment-resistant depression show elevated levels of inflammatory markers in their blood and brain tissue.
In the clinical study of treatment-resistant patients, the drop in TNF-α at 40 minutes after ketamine infusion directly correlated with improvement in depression scores over the following days. Patients whose TNF-α decreased the most saw the greatest reduction in depressive symptoms by days four and five. Patients with treatment-resistant depression who also had chronic pain showed reductions in both TNF-α and IL-6 alongside improvements in mood and pain levels. In animal models of postpartum depression, ketamine reversed depressive behavior while simultaneously reducing IL-6 and markers of oxidative tissue damage in the frontal cortex.
Beyond cytokine reduction, ketamine also appears to counteract the broader glial response to stress. In a rodent model of PTSD, a single dose of ketamine rescued maladaptive changes in both microglia and astrocytes (the brain’s support cells) that occur after acute traumatic stress. It reduced reactive astrogliosis, a process where astrocytes swell and scar brain tissue, and normalized levels of brain growth factors that had been disrupted by the stressful event.
Brain Injury and Neuroprotection
Traumatic brain injury triggers a cascade of neuroinflammation including nerve fiber degeneration, glial cell death, oxidative stress, and a phenomenon called spreading depolarization, where waves of electrical shutdown sweep across injured brain tissue. These depolarization events are a sign of serious neuronal disruption and are associated with worse outcomes.
Clinical studies in TBI patients have found that ketamine infusions at approximately 1.15 mg/kg per hour significantly reduced spreading depolarization events and increased healthy brain wave activity. Lower doses had minimal impact. However, the results across studies were not entirely consistent. Some patients showed unusual electrical patterns like gamma bursts or burst suppression, which complicates the interpretation. The overall evidence suggests ketamine has neuroprotective potential in acute brain injury, but the optimal dosing and timing remain uncertain.
What This Means in Practice
The anti-inflammatory effects of ketamine are real but nuanced. At the low doses used to treat depression (0.5 mg/kg or less), ketamine reduces key inflammatory markers quickly, sometimes within 40 minutes, and those reductions appear to be connected to its mood-lifting effects. It dials down the NF-κB inflammatory pathway, calms overactive microglia, and protects against stress-related glial damage.
But ketamine is not a blanket anti-inflammatory. It selectively reduces some markers like TNF-α while potentially increasing others like IL-6 and IL-1β, especially with repeated or higher doses. And at anesthetic or supratherapeutic levels, it can flip from protective to harmful, actively promoting the very inflammation and cell death it prevents at lower doses. The therapeutic window is real and relatively narrow, which is why ketamine for neuroinflammation-related conditions is administered under medical supervision with careful dose control.